Table 42Change in HbA1c in Avandaryl® (rosiglitazone/glimepiride) or rosiglitazone plus glimepiride trials in adults with type 2 diabetes

Author, year Country
Quality
InterventionHbA1c (%) change from baseline (mean, SD) for FDCP or dual therapyHbA1c change from baseline (mean, SD) for active controlP value of between-group difference
Fixed-dose combination
Chou 2008186
Multinational
Good
Avandaryl®(A): 4 mg/1 mg – 4 mg/4 mg daily

Avandaryl®(B): 4 mg/1 mg – 8 mg/4 mg daily

Glimepiride: 1 mg–4 mg daily

Rosiglitazone: 4 mg–8 mg daily
  1. −2.41 (1.4)
  2. −2.52 (1.4)
Glimep: −1.72 (1.4)

Rosi: −1.75 (1.5)
<0.0001 (All)
Dual therapy
McCluskey 2004187
United States
Fair
Dual therapy (rosi + glimep): 8 mg/1 mg – 8 mg/8 mg daily

Rosiglitazone: 4 mg–8 mg daily
−1.2 (SE −0.1)−0.3 (SE 0.2)<0.001
Range

1 Fair
1 Good
Avandaryl®: 4 mg/1 mg to 8 mg/4 mg daily

Dual therapy: 8 mg/1 mg to 8 mg/8 mg daily
2.52 to1.20.3 to1.75

Abbreviations: SD, standard deviation; FDCP, fixed dose combination product; rosi, rosiglitazone; glimep, glimepiride; SE, standard error.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.